combat
public
health
threat
emerg
coronavirus
cov
develop
antivir
therapi
either
virusspecif
pancov
activ
necessari
import
step
antivir
drug
develop
screen
potenti
inhibitor
cellbas
system
recent
emerg
middl
east
respiratori
syndrom
mer
cov
necessit
adapt
method
use
identifi
antivir
sever
acut
respiratori
syndrom
sar
cov
develop
new
approach
effici
screen
antivir
drug
articl
review
cellbas
assay
use
infecti
viru
surrog
assay
implement
acceler
antivir
develop
merscov
futur
emerg
coronavirus
paper
form
part
seri
invit
articl
antivir
research
sar
mer
year
research
highli
pathogen
human
coronavirus
emerg
coronavirus
may
transmit
directli
bat
human
merscov
capabl
infect
bat
human
cell
directli
bat
human
form
receptor
dipeptidyl
peptidas
iv
support
viral
entri
muller
et
al
raj
et
al
addit
fragment
rnadepend
rna
polymeras
gene
genet
ident
merscov
detect
one
egyptian
tomb
bat
memish
za
mishra
n
oliv
kj
fagbo
sf
kapoor
v
epstein
jh
et
al
dromedari
camel
found
neutral
antibodi
merscov
perhap
link
endem
sourc
viru
intermedi
host
human
merscov
infect
perera
et
al
reusken
et
al
sinc
outbreak
sarscov
extens
effort
antivir
drug
develop
fda
approv
antivir
drug
vaccin
exist
human
coronavirus
review
barnard
kumaki
howev
much
learn
studi
evalu
inhibitor
direct
sarscov
appli
new
emerg
coronavirus
understand
experiment
method
result
studi
perform
screen
sarscov
antivir
guid
current
work
develop
drug
merscov
ultim
identifi
pancoronaviru
inhibitor
cellbas
assay
great
import
develop
effect
antivir
assay
identifi
possibl
antivir
candid
initi
select
vitro
screen
focu
review
outlin
potenti
drug
target
coronaviru
life
cycl
describ
cellbas
assay
use
test
antivir
sarscov
highlight
novel
techniqu
use
evalu
potenti
antivir
merscov
discuss
challeng
face
anticoronavir
drug
develop
coronaviru
genom
encod
mani
druggabl
target
target
highlight
role
replic
cycl
life
cycl
figur
human
dipeptidyl
peptidas
iv
discov
receptor
merscov
receptorbind
domain
rbd
spike
protein
identifi
structur
character
chen
et
al
du
et
al
mou
et
al
crystal
structur
complex
rbd
determin
wang
et
al
review
li
interact
viral
glycoprotein
receptor
target
virus
includ
sarscov
coronavirus
enter
cell
receptor
mediat
endocytosi
membran
fusion
plasma
membran
endocytosi
receptorviru
complex
occur
upon
acidif
endosom
host
proteas
cathepsin
l
activ
cleav
viral
spike
protein
initi
viral
fusion
coronavir
spike
also
activ
extracellular
proteas
trypsin
proteas
present
cell
surfac
type
ii
transmembran
serin
proteas
cleavag
allow
coronavirus
enter
cell
cathepsinindepend
manner
glowacka
et
al
matsuyama
et
al
shulla
et
al
review
simmon
zmora
gierer
heurich
upon
viral
entri
fusion
viral
host
cell
membran
posit
sens
rna
genom
methylcap
polyadenyl
translat
cytoplasm
translat
yield
two
larg
polyprotein
cleav
nonstructur
protein
papainlik
proteas
encod
within
proteas
encod
proteas
drug
target
proteolysi
nonstructur
protein
requir
replic
viru
papainlik
proteas
sarscov
coronavirus
shown
antagon
host
innat
immun
respons
inhibit
papainlik
proteas
stop
viral
replic
may
prevent
antagon
host
innat
immun
respons
barretto
et
al
devaraj
et
al
frieman
ratia
johnston
mesecar
baric
sun
et
al
success
inhibitor
gener
sarscov
pl
pro
pro
gener
genom
copi
subgenom
mrna
synthesi
structur
gene
viral
genom
must
replic
seri
enzym
compris
membraneassoci
replic
transcript
complex
rtc
primas
rnadepend
rna
polymeras
rdrp
helicas
exonucleas
methyltransferas
endoribonucleas
omethyltransferas
protein
enzymat
activ
target
antivir
fact
inhibitor
identifi
block
activ
sarscov
rdrp
helicas
omethyltransferas
replic
genom
gener
subgenom
mrna
sgmrna
structur
accessari
protein
translat
sgmrna
assembl
virion
occur
endoplasm
reticulumgolgi
intermedi
compart
ergic
virion
egress
exosom
pathway
assembl
egress
mechan
target
inhibit
virus
strategi
explor
develop
coronaviru
antivir
viral
glycoprotein
bind
cognat
receptor
spike
protein
mediat
viral
envelop
fusion
cellular
membran
necessari
infect
step
infect
success
target
virus
two
fda
approv
antivir
target
entri
clinic
use
review
henrich
kuritzk
antivir
maraviroc
smallmolecul
antagonist
inhibit
glycoprotein
bind
receptor
use
differ
mechan
antivir
enfuvirtid
inhibit
viral
fusion
interrupt
interact
heptad
repeat
region
within
glycoprotein
partial
base
success
strategi
smallmolecul
peptid
inhibitor
identifi
target
entri
sarscov
review
describ
studi
use
cellbas
screen
method
identifi
inhibitor
abil
evalu
sarscov
entri
specif
inhibitor
advanc
demonstr
pseudotyp
virion
particl
incorpor
protein
sarscov
compet
entri
fukushi
et
al
girogl
et
al
hofmann
et
al
moor
et
al
contrast
previou
cellbas
screen
base
viral
induc
cpe
pseudotyp
lentivir
virion
deliv
genom
express
gfp
luciferas
report
allow
quantit
measur
evalu
coronavir
entri
inhibitor
assay
use
laboratori
involv
work
infecti
cov
use
techniqu
first
demonstr
sarscov
entri
inhibit
achiev
use
piec
sarscov
peptid
design
interact
goal
approach
block
viral
membran
fusion
intermedi
zhu
et
al
studi
demonstr
small
peptid
bind
heptad
repeat
region
sarscov
parallel
mechan
fda
approv
hiv
entri
inhibitor
enfuvirtid
could
inhibit
viral
entri
fusion
addit
peptid
studi
base
amino
acid
sequenc
sarscov
compound
screen
perform
sarscov
entri
use
commerci
screen
divers
compound
compound
screen
chembridg
smallmolecul
inhibitor
found
inhibit
sarscov
entri
base
first
viral
induc
cpe
reduct
prevent
pseudotyp
virion
entri
kao
et
al
shortli
demonstr
smallmolecul
compound
could
target
sarscov
entri
yi
et
al
demonstr
natur
compound
screen
could
also
use
inhibit
sarscov
entri
show
inhibit
smallmolecul
pseudotyp
virion
screen
identifi
two
candid
inhibit
entri
micromolar
rang
util
luciferas
express
lentivir
vector
pseudotyp
protein
molecul
screen
base
luciferas
express
level
transduc
cell
two
molecul
tgg
leuteolin
screen
chines
herbal
librari
shown
antivir
activ
pseudotyp
assay
confirm
live
viru
use
mtt
colorimetr
assay
cytotox
initi
studi
evolv
three
class
inhibitor
studi
small
peptid
block
viral
fusion
interact
sarscov
inhibit
cellular
proteas
cleav
viral
glycoprotein
mediat
entri
small
chemic
compound
interact
sarscov
inhibit
entri
peptid
studi
advanc
identifi
necessari
peptid
high
affin
interact
potent
inhibit
liu
et
al
ni
et
al
struck
axmann
pfefferl
drosten
meyer
ujik
et
al
zheng
et
al
zheng
et
al
develop
peptid
correspond
small
fragment
sarscov
protein
identifi
three
synthet
peptid
inhibitori
properti
peptid
also
addit
inhibitori
effect
preincub
combin
cell
prior
infect
elucid
mechan
inhibit
author
use
molecular
model
specul
peptid
interact
face
sarscov
requir
interact
monom
form
function
trimer
inhibit
interfac
previous
observ
suggest
novel
target
strategi
prevent
mediat
viral
entri
addit
peptid
design
bind
protein
han
et
al
took
opposit
approach
design
peptid
correspond
residu
critic
entri
mediat
han
pennnicholson
cho
use
pseudotyp
mulv
hela
cell
express
wildtyp
alanin
point
mutant
within
determin
mani
charg
residu
within
alpha
helic
residu
inhibitori
effect
viral
entri
importantli
studi
determin
effect
could
seen
minut
adsorpt
commonli
use
minut
adsorpt
time
led
high
background
could
nt
properli
identifi
inhibitor
pseudotyp
assay
base
studi
author
creat
peptid
correspond
amino
acid
residu
determin
peptid
specif
inhibitori
activ
sarscov
pseudotyp
entri
entri
vsvg
psuedotyp
overal
peptid
correspond
sarscov
effect
limit
entri
pseudotyp
wildtyp
sarscov
howev
none
inhibitor
test
anim
model
inhibit
cellular
factor
requir
sarscov
entri
attract
target
could
less
suscept
viral
escap
due
mutat
within
viral
glycoprotein
catalyt
mutant
effect
viral
entri
suggest
enzymat
activ
coronavir
receptor
requir
entri
moor
et
al
sarscov
protein
requir
cleavag
either
extracellularli
trypsin
within
endosom
compart
cathepsin
l
figur
simmon
et
al
determin
cathepsin
l
mediat
sarscov
protein
cleavag
pharmacolog
target
prevent
sarscov
cleavag
entri
simmon
et
al
studi
uniqu
virusviru
membran
fusion
assay
util
assay
involv
two
psuedotyp
virion
one
decor
sarscov
avian
sarcoma
leukosi
viru
aslv
envelop
protein
one
contain
luciferas
express
construct
particl
induc
undergo
fusion
vitro
particl
abl
enter
cell
contain
aslv
receptor
express
luciferas
must
undergon
viral
membran
fusion
upon
mix
two
pseudoparticl
popul
cathepsin
l
respons
cleavag
within
endosom
inhibit
purifi
cathepsin
l
vitro
prevent
viralvir
membran
fusion
pseudoparticl
express
luciferas
detect
author
use
assay
demonstr
cathepsin
l
activ
sarscov
also
endosom
cathepsin
respons
mediat
sarscov
entri
cathepsin
l
continu
target
antivir
develop
sarscov
envelop
virus
cleavag
requir
within
glycoprotein
ebola
viru
shah
et
al
endosom
proteas
proteas
abl
activ
sarscov
activ
host
cell
plasma
membran
allow
sarscov
enter
without
util
cathepsin
l
figur
cellcel
fusion
assay
use
identifi
character
plasma
membran
surfac
factor
use
investig
cell
surfac
fusion
inhibitor
cell
express
sarscov
polymeras
plate
cell
express
luciferas
gfp
report
plasmid
driven
promot
upon
receptor
interact
fusion
cytoplasm
cell
type
mix
allow
transcript
translat
luciferas
gfp
shulla
et
al
simmon
et
al
pseudotyp
virion
use
kawas
et
al
work
identifi
commerci
avail
proteas
inhibitor
target
kawas
shirato
van
der
hoek
taguchi
matsuyama
inhibit
serin
proteas
includ
partial
inhibit
entri
pseudotyp
particl
howev
also
inhibit
cystein
proteas
includ
cathepsin
fulli
inhibit
entri
pseudoparticl
authent
sarscov
target
host
cell
factor
shown
effect
way
prevent
viral
fusion
entri
cell
cultur
final
smallmolecul
inhibitor
screen
develop
target
sarscov
entri
recent
adedeji
et
al
use
sarscov
pseudotyp
hivluc
viru
screen
compound
librari
adedeji
et
al
forti
four
hit
taken
librari
analyz
specif
sarscov
entri
compar
inhibit
vsvg
envelop
hivluc
pseudoviru
initi
compound
found
specif
inhibit
sarscov
counter
screen
highlight
import
identifi
specif
compound
undergo
analysi
posit
hit
initi
screen
vitro
analysi
perform
three
compound
identifi
separ
inhibit
cathepsin
l
activ
inhibit
interact
inhibit
fusion
step
downstream
recognit
feasibl
chemic
compound
inhibit
viru
entri
establish
strategi
develop
efficaci
antivir
especi
hiv
howev
small
compound
remain
rel
unexplor
strategi
respect
coronavirus
overal
target
viral
entri
coronavirus
especi
sarscov
hasbeen
demonstr
use
specif
cellbas
assay
outlin
strategi
util
evalu
peptid
chemic
inhibitor
proteinreceptor
interact
smediat
fusion
host
cell
factor
necessari
mediat
merscov
emerg
coronaviru
entri
entri
fusion
sarscov
genom
translat
two
larg
polyprotein
replic
continu
polyprotein
must
cleav
viral
proteas
either
papainlik
proteas
design
pl
pro
proteas
pro
pro
main
proteas
step
replic
process
target
extens
work
done
identifi
inhibitor
sarscov
replic
review
barnard
kumaki
sarscov
pl
pro
respons
three
cleavag
sarscov
pro
cleav
polyprotein
site
figur
use
proteas
conserv
across
coronavirus
pl
pro
pro
consid
attract
target
antivir
drug
develop
much
antivir
work
perform
coronavir
proteas
done
use
vitro
cell
free
condit
work
crucial
lay
foundat
continu
antivir
develop
review
mesecar
hilgenfeld
colleagu
seri
section
continu
focu
highlight
import
cell
base
assay
techniqu
effici
identifi
valid
antivir
candid
coronaviru
replic
first
sarscov
pl
pro
inhibitor
discov
first
screen
purifi
protein
vitro
character
infect
cell
lysat
assay
chou
et
al
ratia
et
al
determin
inhibitor
character
specif
sarscov
pl
pro
ratia
et
al
util
cell
lysat
experi
combin
purifi
sarscov
pl
pro
cell
lysat
tag
ubiquitinvinyl
sulfon
inhibitor
experi
cell
lysat
incub
tag
ubiquitinvinyl
sulfon
deubiquitin
enzym
coval
link
via
vinyl
sulfon
linkag
tag
ubiquitin
lysat
analyz
western
blot
determin
deubiquitin
enzym
bind
ubiquitin
vinylsulfon
affect
presenc
inhibitor
presenc
specif
sarscov
inhibitor
sarscov
pl
pro
bind
tag
ubiquitin
vinyl
sulfon
shown
decreas
strictli
cellbas
method
use
techniqu
determin
specif
inhibitor
papainlik
proteas
activ
frieman
et
al
took
entir
cellbas
approach
screen
identif
mechanist
evalu
small
compound
librari
sarscov
pl
pro
frieman
et
al
express
activ
sarscov
pl
pro
within
cerevisia
led
slow
growth
phenotyp
basi
screen
inhibit
pl
pro
activ
small
compound
could
revers
slow
growth
phenotyp
growth
measur
optic
densiti
compound
librari
provid
nih
author
gener
candid
compound
analyz
effect
pl
pro
express
toxic
within
cerevisia
base
result
author
screen
compound
cell
activ
sarscov
replic
compound
also
test
three
differ
activ
sarscov
papainlik
proteas
first
drug
test
abil
inhibit
cleavag
synthet
pl
pro
polyprotein
substrat
sarscov
pl
pro
assay
use
tag
cleavag
product
depend
pl
pro
catalyt
activ
visual
western
blot
second
assay
use
deubiquitin
activ
pl
pro
readout
pl
pro
activ
inhibit
cell
transfect
pl
pro
tag
ubiquitin
treat
inhibitor
pl
pro
cleav
ubiquitin
molecul
result
decreas
smear
ubiquitin
protein
increas
smear
inhibitor
block
pl
pro
deubiqutin
activ
final
author
assess
abil
inhibitor
block
interferon
antagon
properti
pl
pro
use
ifnp
luciferas
assay
cell
transfect
either
poli
c
constitut
activ
form
rigi
ifnp
luciferas
report
plpro
treat
inhibitor
plpro
inhibit
ifnp
promot
activ
respons
stimulu
pl
pro
inhibitor
block
abil
pl
pro
inhibit
ifnp
activ
increas
ifnp
promot
activ
seen
cell
base
screen
techniqu
good
tool
assess
mechan
inhibitor
inhibit
papainlik
proteas
within
cell
howev
assay
amen
higherthroughput
analysi
compound
offer
specif
quantit
pl
pro
catalyt
activ
within
cell
critic
attempt
optim
small
compound
build
structur
activ
relationship
sarscov
pro
also
target
extens
effort
gener
specif
antivir
model
sarscov
pro
base
structur
transmiss
gastroenter
viru
tgev
pro
present
likelihood
structur
conserv
rhinovir
pro
inhibitor
bound
effici
pro
later
shown
form
complex
sarscov
pro
anand
ziebuhr
wadhwani
mester
hilgenfeld
yang
et
al
base
biochem
character
enzymat
properti
proteas
much
earli
work
pro
inhibitor
perform
vitro
cellfre
condit
exampl
blanchard
et
al
use
purifi
sarscov
pro
fretbas
vitro
assay
screen
larg
compound
librari
compound
pro
inhibit
blanchard
et
al
multipl
studi
use
live
infect
approach
base
cell
cytotox
work
backward
hit
identifi
mechan
action
identifi
inhibitor
kao
et
al
wu
et
al
experi
like
critic
identif
lead
compound
howev
cellbas
assay
design
measur
proteas
activ
need
identifi
compound
could
efficaci
context
viral
infect
measur
pro
inhibitor
cellbas
assay
lin
et
al
creat
ci
cleavag
luciferas
assay
lin
et
al
involv
creation
express
construct
encod
sarscov
pro
frame
insert
pro
cleavag
site
savlqsgfrk
downstream
luciferas
construct
rational
design
knowledg
luciferas
fuse
larger
protein
activ
substanti
decreas
upon
ci
cleavag
pro
luciferas
polyprotein
liber
luciferas
give
increas
signal
author
demonstr
luciferas
construct
activ
translat
fuse
mutat
pro
cleavag
site
cleavag
site
intact
wit
fold
increas
luciferas
activ
assay
first
demonstr
quantit
readout
pro
activ
proteas
transient
express
within
cell
replicon
develop
sarscov
use
platform
screen
anticoronavir
compound
almazan
et
al
f
ge
luo
liew
hung
f
ge
xiong
lin
zhang
zhang
replicon
contain
sarscov
addit
n
gene
requir
replic
report
cassett
n
gene
report
transcrib
separ
subgenom
messeng
rna
similar
replic
viru
figur
mean
report
synthes
replicon
replic
correctli
sarscov
replicon
either
transfect
incorpor
stabl
cell
line
antivir
screen
replicon
use
approach
address
specif
compound
screen
determin
mechan
action
candid
compound
must
screen
replicas
protein
anoth
system
antivir
also
develop
sarscov
helicas
adedeji
et
al
tanner
et
al
yu
et
al
polymeras
ahn
et
al
te
velthui
et
al
ke
et
al
previou
studi
van
hemert
et
al
establish
protocol
isol
monitor
activ
sarscov
replic
complex
vitro
van
hemert
et
al
studi
perform
te
velthui
et
al
use
protocol
show
zincionophor
inhibit
synthesi
rna
sarscov
rdrp
method
allow
studi
cellproduc
replic
complex
vitro
sinc
outbreak
merscov
adapt
method
use
screen
sarscov
inhibitor
merscov
develop
novel
method
identifi
potenti
antivir
inhibitor
merscov
tabl
entri
coronavirus
includ
sarscov
known
mediat
figur
determin
inhibit
viabl
strategi
prevent
merscov
entri
shirato
et
al
target
activ
camostat
assess
abil
merscov
caus
syncytia
enter
cell
use
qrtpcr
viral
rna
demonstr
inhibit
activ
could
inhibit
merscov
syncytia
format
camostat
combin
inhibitor
cathepsin
l
figur
potent
inhibit
merscov
entri
cell
shirato
kawas
matsuyama
data
repres
first
chemic
inhibit
merscov
entri
use
infecti
merscov
target
host
proteas
target
merscov
receptor
shown
effect
approach
gao
et
al
design
viral
fusion
peptid
inhibitor
heptad
repeat
region
merscov
ohnuma
et
al
creat
monoclon
antibodi
abl
block
merscov
entri
ohnuma
et
al
understand
merscov
infect
influenc
interact
host
cell
josset
et
al
infect
lung
epitheli
cell
line
merscov
sarscov
analyz
host
transcriptom
josset
et
al
approach
identifi
host
factor
inhibitori
compound
exist
could
exploit
antivir
therapeut
valid
put
inhibitor
author
infect
cell
merscov
show
host
kinas
inhibitor
inhibitori
effect
sarscov
merscov
replic
approach
use
identifi
host
cell
factor
benefici
replic
determin
druggabl
target
identifi
exist
inhibitor
target
base
knowledg
cyclophilin
play
import
role
coronavir
infect
pfefferl
et
al
de
wild
et
al
use
cyclosporin
determin
cytotox
result
merscov
infect
possibl
readout
antivir
screen
de
wild
et
al
cyclosporin
abl
prevent
merscov
cytopath
effect
vero
cell
verifi
cpe
read
merscov
infect
possibl
way
screen
antivir
compound
merscov
aid
studi
merscov
biolog
antivir
screen
revers
genet
system
merscov
develop
two
group
almazan
et
al
scobey
et
al
use
revers
genet
allow
creation
virus
express
report
readout
viral
replic
use
screen
antivir
compound
quantit
fashion
demonstr
scobey
et
al
engin
merscov
encod
rfp
gene
express
viral
replic
show
inhibitori
effect
use
infecti
viru
critic
step
develop
antivir
screen
larg
compound
librari
determin
inhibitor
mechan
use
infecti
viru
practic
mani
approach
reli
use
infecti
merscov
way
determin
compound
inhibitori
effect
merscov
highli
pathogen
transmitt
human
human
assay
must
perform
laboratori
far
two
approach
develop
assay
antivir
compound
either
entri
viral
proteas
stage
merscov
lifecycl
without
use
infecti
merscov
first
approach
involv
familiar
pseudotyp
assay
use
evalu
sarscov
entri
inhibitor
gierer
et
al
use
vsvluciferas
pseudotyp
merscov
determin
merscov
util
coronavir
receptor
endosom
cathepsin
facilit
viral
entri
protein
neutral
merscov
infect
patient
serum
zhao
et
al
also
use
pseudotyp
virion
experi
util
hivluciferas
viru
pseudotyp
merscov
use
system
also
show
could
neutral
antibodi
smallmolecul
inhibitor
hiv
entri
inhibitori
properti
transduct
pseudovirion
gao
et
al
use
pseudotyp
virion
determin
hr
target
peptid
inhibit
viral
entri
novel
cellbas
approach
assay
coronavir
proteas
activ
develop
kilianski
et
al
use
determin
previous
identifi
sarscov
proteas
inhibitor
activ
merscov
proteas
kilianski
mielech
deng
baker
experi
util
circularli
permut
luciferas
construct
insert
cleavag
site
correspond
either
papainlik
proteas
recognit
site
express
vector
merscov
pl
pro
pro
abl
cleav
respect
biosensor
transfect
togeth
endpoint
dualluciferas
assay
renilla
luciferas
transfect
control
live
cell
assay
use
cell
permeabl
luciferas
substrat
show
luciferas
activ
merscov
proteas
present
assay
use
test
previous
identifi
sarscov
pl
pro
pro
inhibitor
pl
pro
inhibitor
effect
activ
merscov
pl
pro
pro
inhibitor
show
inhibitori
activ
merscov
pro
first
demonstr
efficaci
antivir
compound
specif
merscov
enzym
lead
sarscov
specif
compound
test
applic
assay
limit
merscov
viral
papainlik
proteas
sarscov
also
activ
luciferas
construct
cellbas
biosensor
assay
especi
use
use
level
studi
effect
compound
inhibitor
coronavir
proteas
context
host
cell
mani
challeng
current
face
scientist
develop
coronavir
especi
merscov
antivir
drug
highlight
need
valid
cellbas
assay
use
acceler
antivir
compound
discoveri
face
emerg
coronaviru
infect
tabl
one
issu
merscov
antivir
design
suitabl
anim
model
exist
rhesu
macaqu
infect
merscov
exhibit
symptom
respond
therapi
de
wit
et
al
falzarano
et
al
munster
de
wit
feldmann
howev
symptom
transient
complet
reflect
sever
diseas
human
unlik
sarscov
de
wit
et
al
demonstr
merscov
establish
product
infect
syrian
hamster
de
wit
et
al
date
publish
observ
merscov
infect
small
anim
model
mice
ferret
addit
work
need
done
develop
broadspectrum
inhibitor
would
work
common
human
coronavir
pathogen
like
develop
inhibitor
also
target
common
virus
would
allow
clinic
trial
effect
antivir
drug
endem
possibl
emerg
coronavirus
goal
review
highlight
cellbas
assay
use
evalu
coronaviru
antivir
also
bring
light
novel
techniqu
use
field
highlight
method
applic
techniqu
assist
gener
new
assay
rapid
develop
coronavir
inhibitor
futur
use
public
health
threat
merscov
futur
emerg
coronavirus
continu
persist
adapt
knowledg
methodolog
sarscov
research
also
develop
novel
method
screen
antivir
import
achiev
goal
creat
broadspectrum
anticoronavir
drug
approv
human
use
coronaviru
entri
proteolyt
process
rna
synthesi
enzym
attract
target
antivir
cellbas
screen
use
identifi
evalu
antivir
sarscov
merscov
new
approach
avail
character
pancoronaviru
inhibitor
cov
proteas
antivir
sarscov
may
efficaci
merscov
emerg
coronavirus
target
viral
entri
includ
viral
spikehost
receptor
interact
host
proteas
cleav
viral
spike
mediat
fusion
viral
replicas
polyprotein
process
target
inhibit
papainlik
proteas
enzymat
activ
replicationtranscript
complex
rtc
convolut
membran
doublemembran
vesicl
also
attract
target
inhibitor
